Androgen deprivation therapy in men with node-positive prostate cancer treated with postoperative radiotherapy Journal Article
| Authors: | Bravi, C. A.; Tin, A.; Vertosick, E.; Mazzone, E.; Bandini, M.; Dell'Oglio, P.; Stabile, A.; Gandaglia, G.; Fossati, N.; Sjoberg, D.; Touijer, K.; Cozzarini, C.; Briganti, A.; Montorsi, F.; Eastham, J.; Vickers, A. |
| Article Title: | Androgen deprivation therapy in men with node-positive prostate cancer treated with postoperative radiotherapy |
| Abstract: | Background: In men with node-positive prostate cancer after radical prostatectomy there are limited data on the value of adding androgen deprivation therapy (ADT) to postoperative radiotherapy. Objective: To determine whether there is a clear oncologic benefit to ADT in the setting of node-positive prostate cancer treated with postoperative radiotherapy. Methods: We analyzed data for 372 prostate cancer patients treated at San Raffaele Hospital with postoperative radiotherapy for node-positive disease after radical prostatectomy, 272 received both ADT and radiotherapy. Eighty-six men were followed without an event for more than 10 years. Results: Patients who received postoperative radiotherapy + ADT had more aggressive disease, with higher preoperative PSA level, higher rate of ISUP grade 5, pT3b-T4 tumors and ≥3 positive nodes. At multivariable Cox regression, the comparison between men treated by postoperative radiotherapy + ADT vs. radiotherapy alone did not show a significant difference for overall (hazards ratio: 0.91; 95% confidence interval: 0.45, 1.84; P = 0.8) and cancer-specific survival (hazards ratio: 5.39; 95% confidence intervalI: 0.70, 41.39; P = 0.11). These results remained consistent in a number of sensitivity analyses, including propensity score matching. Consideration of 95% CIs suggests that a clinically significant benefit of ADT in node-positive patients receiving radiotherapy after surgery is unlikely. Conclusions: We can exclude the sort of large survival benefit that would be required to justify the risks and toxicities of ADT in men with node-positive disease receiving postoperative radiotherapy. Awaiting larger and more powered studies on this topic, men with pN+ prostate cancer treated with postoperative radiotherapy should not receive ADT outside well-controlled clinical trials. © 2019 Elsevier Inc. |
| Keywords: | controlled study; aged; cancer surgery; major clinical study; overall survival; cancer patient; cancer radiotherapy; comparative study; postoperative care; follow up; lymph node metastasis; lymph node dissection; pelvis lymph node; preoperative evaluation; prostate specific antigen; retrospective study; cancer mortality; prostate cancer; prostatectomy; cancer specific survival; radical prostatectomy; gonadorelin agonist; orchiectomy; androgen deprivation therapy; biochemical recurrence; postoperative radiotherapy; antineoplastic hormone agonists and antagonists; surgical margin; clinical outcome; human; male; priority journal; article; all cause mortality; node-positive prostate cancer |
| Journal Title: | Urologic Oncology: Seminars and Original Investigations |
| Volume: | 38 |
| Issue: | 4 |
| ISSN: | 1078-1439 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2020-04-01 |
| Start Page: | 204 |
| End Page: | 209 |
| Language: | English |
| DOI: | 10.1016/j.urolonc.2019.09.018 |
| PUBMED: | 31653565 |
| PROVIDER: | scopus |
| PMCID: | PMC8142939 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 May 2020 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work